Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In ...
Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination ...
Dual-targeted therapy plus chemo boosts response rate in BRAF-mutated metastatic colorectal ...
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...
Pfizer reports positive outcomes from trial of mCRC combination therapy
Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...
The Pharma Letter17 小时
Positive Phase III results for Pfizer’s Braftovi combo
US pharma giant Pfizer on Saturday announced positive results from the Phase III BREAKWATER trial evaluating its Braftovi ...
PharmiWeb18 小时
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with ...
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 ...
来自MSN22 小时
Triple Therapy in Metastatic CRC With BRAF Mutations: The New Standard of Care?
First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...